ArticleKidney3602026
Is Age Just a Number?: A Comparative Analysis of Glomerular Disease Across Ages from the Cure Glomerulonephropathy Network.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Why Age Is Not Just a Number in Glomerular Disease.Kidney360 · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
key pointsAdolescents and young adults with glomerular disease have unique clinical features distinct from children and older adults. Patterns of relapse, remission, and changes in kidney function differ by age and glomerular disease type. Traditional pediatric-adult cutoffs often overlook key differences; care and research should reflect a continuum across the lifespan.
backgroundGlomerular disease (GD) is a prominent cause of kidney disease in adolescents and young adults (AYAs), yet there is limited information on how this population fares compared with children and older adults.
methodsWe analyzed data from Cure Glomerulonephropathy, a prospective cohort of patients of all ages with biopsy-proven GD. Patients with minimal change disease (MCD), FSGS, and IgA nephropathy (IgAN) were included. Patients were stratified into pediatric (≤13), AYA (14-25), and adult (≥26) groups and compared by demographic, clinical, and disease characteristics. Associations between age group and relapse rate, change in kidney function, and time to remission were assessed using multivariate negative binomial, linear mixed effects, and Cox proportional hazards models, respectively, stratified by disease type.
resultsOur study included 1868 patients (562 pediatric, 397 AYA, and 909 adults). The median follow-up time was 4.9 years. Adults with MCD had fewer relapses (incidence rate ratio [IRR], 0.61; 95% confidence interval [CI], 0.41 to 0.91; P = 0.01), while there was no difference between pediatric participants with MCD (IRR, 1.23; 95% CI, 0.85 to 1.79; P = 0.28) compared with AYA. Adults with IgAN had fewer relapses than AYA (IRR, 0.55; 95% CI, 0.33 to 0.94; P = 0.03). AYA had faster decline in kidney function compared with pediatric participants with FSGS (1.7 versus 0.3 ml/min per 1.73 m 2 per year, P = 0.008) and IgAN (1.5 versus 0.1 ml/min per 1.73 m 2 increase per year, P = 0.002). Pediatric participants with MCD achieved first observed remission sooner compared with AYA (hazard ratio, 2.18; 95% CI, 1.03 to 4.63; P = 0.04). Adults with IgAN were slower to achieve first observed remission compared with AYA (hazard ratio, 0.58; 95% CI, 0.37 to 0.91; P = 0.02).
conclusionsAYA with GD exhibit distinct clinical patterns compared with the pediatric and adult age groups, underscoring the need to approach care and research along an age-related continuum rather than a binary framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.